Eli Lilly and Company

The Salk Institute Biotechnology Industrial Associates, Inc.

Applied Molecular Evolution

Applied Molecule Evolution, Inc.

Craig Duane Dickinson

David A Driver

Ryan James Darling

Gregory Alan Lazar

Jonathan Wesley Day

Andrew Ihor Korytko

John Michael Beals

David Bruce Baldwin

Malgorzata Donata Gonciarz

Alain Philippe Vasserot

David Matthew Marquis

Jeffry Dean Watkins

Ying Tang

Jirong Lu

Julian Davies

Peter Edward Vaillancourt

Radmila Micanovic

Kristine Kay Kikly

Bryan Edward Jones

Kathryn J Elliott

Leona C Fitzmaurice

Catherine Brautigam Beidler

Stuart W Bright

Lihua Huang

Scott William Rowlinson

Yoshihiro Konno

William Owen Butler

T Erik Mirkov

Maigorzata Donata Gonciarz

Theodore E Mirkov

Stuart Willis Bright

David Albert Driver

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

Fusion proteins

Fusion proteins and methods of use

This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.

Fibroblast growth factor 21 variant, composition , and uses thereof

This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.

Fibroblast growth factor 21 proteins

This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.

Fibroblast growth factor 21 variants

Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability

TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

Methods of using TGF-&#x3b2; 1 binding compositions

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.

Anti-IL-23 antibodies

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.

Humanized anti-IL-1 beta antibodies

Antibodies to TGF-beta 1

Humanized anti-IL-1&#x3b2; antibodies

Transgenic plants that are modified to produce fruits that have altered levels of soluble solids compared to non-transgenic species of the same species are provided. The transgenic plants are modified by introduction of DNA constructs that encode invertase operatively linked to DNA encoding regulatory regions that direct transcription of the DNA encoding invertase and to DNA encoding sequences that direct proper processing of the invertase through the secretory pathways of the plant and targeting of the invertase to the vacuole. In particular, DNA constructs encoding tomato plant vacuolar invertase in operative linkage with a developmentally regulated promoter region are provided. Preferred regulatory and structural DNA is obtained from genomic DNA clones and cDNA clones encoding tomato fruit vacuolar invertases from the commercial tomato plant, Lycopersicon esculentum, and wild tomato plant, Lycopersicon pimpinellifolium. Probes derived from the genomic DNA and cDNA, antibodies specific for tomato fruit invertase, and uses therefore, are also provided.

Invertase genes and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Craig Duane Dickinson